Liver enzyme inducing anticonvulsant drug use is associated with prevalent vertebral fracture
Main finding · Prevalence of ≥1 vertebral fracture, ≥2 years of prior useResult — go to the resultOdds ratio 1.48 95% CI 1.04–2.10Authors' conclusion
LEI anticonvulsant use for ≥ 2 years is associated with higher vertebral fracture prevalence.
Study context
- Population
- Individuals who had bone densitometry with vertebral fracture assessment (VFA) between 2010 and 2018 (mean age 76.1 years, 94% female)
- Participants
- 11,822 individuals
- Exposure
- Prior LEI anticonvulsant use vs non-LEI anticonvulsant and other benzodiazepine use
- LEI anticonvulsantsn = 538
- Non-LEI anticonvulsantsn = 2,786
- Other benzodiazepinesn = 5,082
- Outcome
- Prevalence of vertebral fracture on densitometric lateral spine VFA images (modified ABQ method) by duration of prior anticonvulsant use
Methodological detailslinked pharmacy records, logistic regression
- Linked pharmacy records
- Logistic regression
Main finding
As reported in the abstract
Prevalence of ≥1 vertebral fracture, ≥2 years of prior use
Odds ratio
1.48
95% CI 1.04–2.10
By group
Prior LEI anticonvulsant usevs non-LEI anticonvulsant and other benzodiazepine use
OR 1.48 (95% CI 1.04–2.10)
- Prevalence of ≥1 vertebral fracture, entire analytic cohort
- 16.1%
Observational data: associations, not effects.
Original publication
Liver enzyme inducing anticonvulsant drug use is associated with prevalent vertebral fracture. Osteoporos Int. Published 28 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →